Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 6/2017

01-12-2017 | Research Article

[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients

Authors: Jan-Carlo Janssen, Nadine Woythal, Sebastian Meißner, Vikas Prasad, Winfried Brenner, Gerd Diederichs, Bernd Hamm, Marcus R. Makowski

Published in: Molecular Imaging and Biology | Issue 6/2017

Login to get access

Abstract

Purpose

The aim of this study was to evaluate potential differences in “Glu-NH-CO-NH-Lys” radio-labeled with [68Ga]gallium N,N-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N-diacetic acid ([68Ga]PSMA-HBED-CC) uptake in osteolytic, osteoblastic, mixed, and bone marrow metastases in prostate cancer (PC) patients.

Procedures

This retrospective study was approved by the local ethics committee. Patients who received [68Ga]PSMA-HBED-CC positron emission tomography/computed tomography ([68Ga]PSMA-PET/CT) with at least one positive bone metastasis were included in this study. Only patients who have not received systemic therapy for their PC were included. Bone metastases had to be confirmed by at least one other imaging modality or follow-up investigation. The maximum standardized uptake value (SUVmax) and mean Hounsfield units (HUmean) of each metastasis were measured. Based on CT, each metastasis was classified as osteolytic (OL), osteoblastic (OB), bone marrow (BM), or mixed (M).

Results

One hundred fifty-four bone metastases in 30 patients were evaluated. Eighty out of 154 (51.9%) metastases were classified as OB, 21/154 (13.6%) as OL, 23/154 (14.9%) as M, and 30/154 (19.5%) as BM. The SUVmax for the different types of metastases were 10.6 ± 7.07 (OB), 24.0 ± 19.3 (OL), 16.0 ± 21.0 (M), and 14.7 ± 9.9 (BM). The SUVmax of OB vs. OL and OB vs. BM metastases differed significantly (p ≤ 0.025). A significant negative correlation between HUmean and SUVmax (r = −0.23, p < 0.05) was measured.

Conclusions

[68Ga]PSMA-HBED-CC uptake is higher in osteolytic and bone marrow metastases compared to osteoblastic metastases. Information derived from [68Ga]PSMA-PET and CT complement each other for the reliable diagnosis of the different types of bone metastases in PC patients.
Literature
1.
Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRefPubMed
2.
Bubendorf L, Schopfer A, Wagner U et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578–583CrossRefPubMed
3.
Carlin BI, Andriole GL (2000) The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88:2989–2994CrossRefPubMed
4.
Charhon SA, Chapuy MC, Delvin EE et al (1983) Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51:918–924CrossRefPubMed
5.
Dushyanthen S, Cossigny DA, Quan GM (2013) The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer. Cancer Growth Metastasis 6:61–80PubMedPubMedCentral
6.
Ibrahim T, Flamini E, Mercatali L et al (2010) Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 116:1406–1418CrossRefPubMed
7.
Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593CrossRefPubMed
8.
Roodman GD (2004) Mechanisms of bone metastasis. Discov Med 4:144–148PubMed
9.
Roudier MP, Vesselle H, True LD et al (2003) Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 20:171–180CrossRefPubMed
10.
11.
12.
Lange MB, Nielsen ML, Andersen JD et al (2016) Diagnostic accuracy of imaging methods for the diagnosis of skeletal malignancies: a retrospective analysis against a pathology-proven reference. Eur J Radiol 85:61–67CrossRefPubMed
13.
Evangelista L, Panunzio A, Polverosi R et al (2012) Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging. Biomed Pharmacother 66:448–453CrossRefPubMed
14.
Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486–495CrossRefPubMed
15.
Eder M, Neels O, Muller M et al (2014) Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel) 7:779–796CrossRef
16.
Eder M, Schafer M, Bauder-Wust U et al (2012) 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688–697CrossRefPubMed
17.
Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56:668–674CrossRefPubMed
18.
Maurer T, Gschwend JE, Rauscher I et al (2016) Diagnostic efficacy of 68Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195:1436–1443CrossRefPubMed
19.
Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209CrossRefPubMed
20.
Prasad V, Steffen IG, Diederichs G et al (2016) Biodistribution of [68Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol Imaging Biol 18:428–436CrossRefPubMed
21.
Pyka T, Okamoto S, Dahlbender M et al (2016) Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43:2114–2121CrossRefPubMed
22.
Dietlein M, Kobe C, Kuhnert G et al (2015) Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol 17:575–584CrossRefPubMedPubMedCentral
23.
Ceci F, Castellucci P, Graziani T et al (2015) 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer. Clin Nucl Med 40:e265–e270CrossRefPubMed
24.
Saad F, Clarke N, Colombel M (2006) Natural history and treatment of bone complications in prostate cancer. Eur Urol 49:429–440CrossRefPubMed
25.
26.
27.
Zhang J, Dai J, Qi Y et al (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235–1244CrossRefPubMedPubMedCentral
28.
Smith MR, Saad F, Coleman R et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39–46CrossRefPubMed
29.
Fogelman I (1980) Skeletal uptake of diphosphonate: a review. Eur J Nucl Med 5:473–476PubMed
30.
Cook GJ, Fogelman I (2001) The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med 31:206–211CrossRefPubMed
31.
Ahmadzadehfar H, Azgomi K, Hauser S et al (2017) 68Ga-PSMA-11 PET as a gatekeeper for the treatment of metastatic prostate cancer with 223Ra: proof of concept. J Nucl Med 58:438–444CrossRefPubMed
32.
Ghanem N, Uhl M, Brink I et al (2005) Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 55:41–55CrossRefPubMed
33.
Rahbar K, Ahmadzadehfar H, Kratochwil C et al (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85–90CrossRefPubMed
34.
Benesova M, Schafer M, Bauder-Wust U et al (2015) Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 56:914–920CrossRefPubMed
35.
Okamoto S, Thieme A, Allmann J et al (2017) Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions. J Nucl Med 58:445–450CrossRefPubMed
36.
Scarpa L, Buxbaum S, Kendler D et al (2017) The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. Eur J Nucl Med Mol Imaging 44:788–800CrossRefPubMed
37.
Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc-99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75CrossRefPubMed
38.
Woo S, Kim SY, Kim SH, Cho JY (2016) Journal club: identification of bone metastasis with routine prostate MRI: a study of patients with newly diagnosed prostate cancer. AJR Am J Roentgenol 206:1156–1163CrossRefPubMed
39.
Blazak JK, Thomas P (2016) Paget disease: a potential pitfall in PSMA PET for prostate cancer. Clin Nucl Med 41:699–700CrossRefPubMed
40.
Gykiere P, Goethals L, Everaert H (2016) Healing sacral fracture masquerading as metastatic bone disease on a 68Ga-PSMA PET/CT. Clin Nucl Med 41:e346–e347CrossRefPubMed
41.
Artigas C, Otte FX, Lemort M et al (2017) Vertebral hemangioma mimicking bone metastasis in 68Ga-PSMA ligand PET/CT. Clin Nucl Med 42:368–370CrossRefPubMed
42.
Fendler WP, Calais J, Allen-Auerbach M et al (2017) 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med. doi:10.​2967/​jnumed.​117.​190827
Metadata
Title
[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients
Authors
Jan-Carlo Janssen
Nadine Woythal
Sebastian Meißner
Vikas Prasad
Winfried Brenner
Gerd Diederichs
Bernd Hamm
Marcus R. Makowski
Publication date
01-12-2017
Publisher
Springer US
Published in
Molecular Imaging and Biology / Issue 6/2017
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-017-1101-y

Other articles of this Issue 6/2017

Molecular Imaging and Biology 6/2017 Go to the issue

Research Article

Influence of Co-57 and CT Transmission Measurements on the Quantification Accuracy and Partial Volume Effect of a Small Animal PET Scanner

Research Article

Validation of Bevacizumab Therapy Effect on Colon Cancer Subtypes by Using Whole Body Imaging in Mice

Research Article

Quantification of Tau Load Using [18F]AV1451 PET

Brief Article

A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [18F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer

Research Article

Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2

Erratum

Erratum to: Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2